Asia Pacific Organ Preservation Solution Market

The Asia Pacific organ preservation solution market was valued at US$ 37,978.81 thousand in 2023 and is expected to reach US$ 81,199.78 thousand by 2031; it is estimated to register a CAGR of 10.1% from 2023 to 2031.

Strategic Initiatives by Market Players Fuels Asia Pacific Organ Preservation Solution Market

Various market players focus on product launches or strategic collaborations to develop advanced products that help ease the treatment of chronic disorders. There have been various recent developments, such as product launches, mergers, and acquisitions in recent years.

• In April 2022, TransMedics Group, Inc. received premarket FDA approval for its OCS Heart System for using it with organs procured from donors after circulatory death. The OCS Heart System is approved with the extended clinical indication for ex vivo reanimation, functional monitoring, and beating-heart preservation of donors-after-circulatory-death (DCD) hearts.
• In August 2023, Paragonix Technologies, a leading organ transplant company, received FDA clearance for its next-generation donor lung preservation system—BAROguard. The BAROguard system combines Paragonix's advanced hypothermic preservation technology with automated continuous and active airway pressure control. This control ensures the maintenance of optimal temperature range and a clinically recommended inflation pressure range for donor's lungs throughout their transfer from donors to recipients. This novel combination of advanced technologies further reinforces the company's ongoing commitment to improving and redefining the standard of care within the field of transplant medicine.
• In April 2024, the Mayo Clinic and the Terasaki Institute for Biomedical Innovation collaborated to improve organ transplant outcomes. Mayo Clinic biomedical researchers and Terasaki Institute scientists plan to collaborate on two main study areas: real-time monitoring of donated organ health from procurement to transplant surgery and the development of predictive technologies to identify transplant recipients with a higher risk of rejection. This will involve creating prognostic signatures and assays for antibody-mediated rejection of organ transplants. The initial projects are expected to be completed within 24–30 months.

Thus, a surge in product approvals, launches, and strategic collaborations is likely to create considerable growth opportunities for the organ preservation solution market in the future.

Asia Pacific Organ Preservation Solution Market Overview

The organ preservation solution market in Asia Pacific is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The market growth in the region is attributed to the growing number of organ transplantations across several countries in Asia Pacific, increasing aging population, rising prevalence of chronic diseases that lead to organ failure, and increasing developments and improvements in organ preservation solutions. China is expected to be the largest market for organ preservation solutions in Asia Pacific. The market growth in the country is attributed to the high prevalence of chronic diseases seeking organ transplantation. According to a recent study, "Chronic Illness and Ageing in China," China's population is aging, and chronic illnesses are increasingly prevalent in the country. The proportion of people aged 60 years and above in China is expected to rise from 12.4% to 28% from 2010 to 2040. In China, ~80% of deaths of people aged 60 years are reported due to chronic noncommunicable diseases (NCDs). Chronic obstructive pulmonary disease (COPD), stroke, ischemic heart disease, and type 2 diabetes are among the most prevalent diseases in the country. China has a greater rate of liver cancer than other countries across the world. According to the World Health Organization, ~400,000 people are diagnosed with liver cancer, and around 368,000 people die due to the disease in China every year. Although accounting for less than 20% of the global population, China accounts for nearly half of all new liver cancer cases. Hepatocellular carcinoma (HCC) represents roughly 90 % of all occurrences of primary liver cancer. It develops mainly in those patients with cirrhosis, or scarring, due to chronic hepatitis B or C. Chronic diseases such as diabetes and liver cancer lead to organ damage. Therefore, the need for organ transplants has increased in China, bolstering the demand for organ preservation solutions.

Asia Pacific Organ Preservation Solution Market Revenue and Forecast to 2031 (US$ Thousand)

Asia Pacific Organ Preservation Solution Strategic Insights

Strategic insights for the Asia Pacific Organ Preservation Solution provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Organ Preservation Solution Report Scope

Asia Pacific Organ Preservation Solution Regional Insights

The geographic scope of the Asia Pacific Organ Preservation Solution refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Asia Pacific Organ Preservation Solution Market Segmentation

The Asia Pacific organ preservation solution market is categorized into product, application, type, end user, and country.

Based on product, the Asia Pacific organ preservation solution market is categorized into University of Wisconsin solution, custodiol HTK, Perfadex, Hypothermosol, and others. The University of Wisconsin segment held the largest market share in 2023.

In terms of application, the Asia Pacific organ preservation solution market is segmented into static cold storage, hypothermic machine perfusion, normothermic machine perfusion, and others. The static cold storage segment held the largest market share in 2023.

By type, the Asia Pacific organ preservation solution market is categorized into kidneys, liver, lungs, heart, and others. The kidneys segment held the largest market share in 2023.

Based on end user, the Asia Pacific organ preservation solution market is segmented into organ transplant centers, hospitals, and specialty clinics. The organ transplant centers segment held the largest market share in 2023.

By country, the Asia Pacific organ preservation solution market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific organ preservation solution market share in 2023.

XVIVO Perfusion, TransMedics, Dr. Franz Koehler Chemie GmbH, Accord Healthcare, and Shanghai Genext Pharmaceutical Technology, are among the leading companies operating in the Asia Pacific organ preservation solution market.